A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
The Research Topic will explore emerging technologies such as advanced MRI, fMRI, PET, CT ... Epilepsy and Seizures · Dyslexia · Dementia · Cerebral Aneurysm We encourage submissions that explore: · ...
Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million ...
Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.
We asked Dr. Joanne Pike, CEO of the Alzheimer's Association to help explain the challenges and hopes when it comes to this debilitating disease.
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
An 80-something patient came in for an annual visit recently and was worried that recent memory lapses might be symptoms of ...
Should Alzheimer’s be diagnosed without symptoms? Proposal to rely on blood tests roils scientists
Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...
The report by GlobalData, a data and analytics company, offers accessible alternatives to PET scans and cerebrospinal fluid ...
In the UK, people living with certain types of dementia, can be prescribed treatments to help manage their symptoms. These are known as symptomatic treatments. They include donepezil (part of a family ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback